

# **Clinical Trial Imaging Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product and Service (Trial Design Consulting Services, Read Analysis Services, Operational Imaging Services, Imaging Software), By Modality (Magnetic Resonance Imaging, Computed Tomography, Ultrasound, Positron Emission Tomography, X-Ray, Echocardiography, Other Modalities), By End-User (Pharmaceutical & Biotechnology Companies, Medical Device Manufacturers, Academic and Government Research Institute), By Region, By Competition, 2019-2029F**

<https://marketpublishers.com/r/C5B6A71CA7B3EN.html>

Date: April 2024

Pages: 183

Price: US\$ 4,900.00 (Single User License)

ID: C5B6A71CA7B3EN

## **Abstracts**

Global Clinical Trial Imaging Market was valued at USD 1.10 billion in 2023 and is anticipated to grow with a CAGR of 7.23% through 2029. Clinical trials are an important part of the drug development process. However, the cost of conducting clinical trials has increased in the recent years. Therefore, clinical trial imaging is emerging as an alternative measure which can help reduce the cost of drug trial and thus improve the timeline of clinical trials. The global clinical trial imaging market is expected to witness significant growth during the forecast period due to increased spending for research and development and increasing number of pharmaceutical and biotechnological industries. In addition, increasing number of contract research organizations has further boosted the market growth. However, high cost of the imaging systems hampers the market growth.

## Key Market Drivers

### Rising Demand for Innovative Therapies

The quest for innovative therapies has led to a surge in clinical trial activity across various therapeutic areas, including oncology, neurology, cardiology, and rare diseases. These trials often require advanced imaging techniques to evaluate the safety and efficacy of new treatments. Consequently, the growing number of clinical trials directly fuels the demand for clinical trial imaging services and technologies. Many innovative therapies, such as targeted biologics, gene therapies, and immunotherapies, are highly complex and require precise monitoring. Imaging technologies like MRI, PET scans, and CT scans enable researchers to assess the response of patients to these novel treatments, track disease progression, and detect early signs of adverse events. The development of innovative therapies often aligns with the principles of precision medicine, where treatments are tailored to individual patients based on their genetic, molecular, and clinical characteristics. Imaging is crucial for patient stratification, identifying suitable candidates for therapies, and monitoring treatment responses on an individualized level. Early detection and diagnosis are key to the success of many innovative therapies, especially in diseases like cancer. Advanced imaging techniques allow for the early identification of diseases and provide valuable insights into disease staging, helping clinicians make informed decisions about treatment strategies. Clinical trials for innovative therapies must rigorously assess safety profiles. Imaging plays a critical role in identifying and monitoring potential side effects or adverse events, contributing to a comprehensive evaluation of a therapy's safety and tolerability. Imaging provides objective and quantifiable data, reducing subjectivity in assessing treatment outcomes. This is particularly important in trials for innovative therapies, where accurate data on efficacy and safety are essential for regulatory approvals and market acceptance. Pharmaceutical and biotechnology companies recognize the importance of incorporating advanced imaging technologies into their clinical trial strategies. Doing so not only improves the chances of successful trials but also provides a competitive edge in the race to bring innovative therapies to market.

### Rising Demand for Precision Medicine

Precision medicine relies on tailoring treatments to individual patients based on their genetic, molecular, and clinical characteristics. As a result, clinical trials in precision medicine are often more complex and require advanced imaging techniques to stratify patients accurately, monitor treatment responses, and assess the impact of therapies at

a personalized level. Precision medicine aims to identify patient subgroups that are most likely to respond to specific treatments. Imaging technologies play a critical role in identifying biomarkers and imaging characteristics that can help stratify patients based on their likelihood of responding to a particular therapy. This enables more efficient and targeted clinical trials. In precision medicine, companion diagnostics are frequently used to select patients who are most likely to benefit from a specific therapy. Imaging biomarkers and imaging-guided diagnostics are becoming increasingly important in companion diagnostic development, thus boosting the demand for clinical trial imaging services. Early detection of diseases and monitoring of disease progression are fundamental aspects of precision medicine. Imaging technologies, such as MRI, PET, and CT scans, provide non-invasive and quantitative methods for early disease diagnosis, tracking changes over time, and assessing treatment responses. Precision medicine relies on personalized treatment plans for patients. Imaging data helps healthcare providers tailor treatment strategies to individual patients by visualizing the location and extent of disease, allowing for more targeted interventions, and optimized therapeutic regimens. Precision medicine therapies often target specific molecular pathways, making safety and efficacy assessments crucial. Imaging allows for the visualization of treatment effects on target tissues, helping researchers and clinicians evaluate therapy responses, potential side effects, and overall treatment outcomes.

### Advancements in Imaging Technology

Technological advancements in imaging, such as higher resolution, improved contrast, and reduced noise, result in more accurate and detailed images. This enhanced data quality is critical for clinical trials as it allows for better visualization and analysis of anatomical and pathological changes, leading to more reliable trial outcomes. The integration of multiple imaging modalities (e.g., MRI, CT, PET, and ultrasound) into clinical trial protocols has become more feasible due to technological progress. This enables researchers to gather comprehensive data on disease progression and treatment responses, enhancing the effectiveness of trials. The integration of artificial intelligence (AI) and machine learning algorithms into imaging technology has revolutionized clinical trial imaging. AI can automate image analysis, detect subtle changes, and provide quantitative measurements, speeding up data processing and reducing human error. Advancements in imaging technology have facilitated remote data acquisition and analysis, allowing for decentralized clinical trials. Patients can undergo imaging procedures at local facilities, and the data can be securely transmitted and analyzed, increasing trial accessibility, and reducing the burden on patients. Emerging technologies enable real-time imaging during surgical and interventional procedures. This is particularly important in trials involving medical devices or minimally

invasive techniques, as it ensures the safety and efficacy of these interventions. Compact and portable imaging devices have been developed, enabling point-of-care imaging in clinical trials. These devices are especially valuable for trials conducted in resource-limited settings or for assessing patients in their homes. Advanced imaging technologies contribute to the discovery of novel biomarkers for disease diagnosis, prognosis, and treatment response prediction. These biomarkers are invaluable in tailoring treatment plans and patient stratification in clinical trials. Advanced imaging technologies facilitate the development of 3D models and simulations, allowing researchers to study disease progression and treatment effects in a virtual environment. This accelerates pre-clinical research and informs trial design.

## Key Market Challenges

### Enhanced Data Quality and Precision

Regulatory bodies like the FDA and EMA require clinical trials to meet stringent standards for data quality and precision. Having high-quality imaging data is crucial for obtaining regulatory approvals for new drugs and medical devices. Therefore, improved data quality facilitates compliance and accelerates the approval process. Inaccurate or imprecise imaging data can lead to erroneous conclusions about a treatment's effectiveness or safety. High-quality and precise data ensure that treatment outcomes are accurately assessed, leading to more reliable results and informed decision-making. Ensuring the precision of imaging data is paramount for patient safety. Accurate diagnoses and treatment assessments reduce the risk of adverse events and ensure that patients receive appropriate care during clinical trials. The credibility of clinical trial results is essential for attracting investment, partnerships, and participation from pharmaceutical companies, research institutions, and patients. High-quality imaging data enhance the credibility and trustworthiness of trial outcomes. Precise and reliable imaging data enable researchers to identify successful drug candidates more quickly and accurately. This efficiency is a key driver for pharmaceutical companies looking to streamline drug development processes. While advanced imaging technologies can be costly to implement initially, the long-term benefits of precise data include cost savings. Avoiding the need for additional, potentially costly, follow-up studies due to inaccurate results is economically advantageous.

### Remote Imaging and Telemedicine

Remote imaging and telemedicine allow for decentralized clinical trials, making it easier to recruit and involve participants who may be geographically distant from trial centers.

This increases the diversity of patient populations and expands the potential participant pool, promoting growth in the clinical trial imaging market. Telemedicine and remote imaging reduce the burden on patients by enabling them to participate in clinical trials without the need for frequent travel to trial sites. This convenience can enhance patient recruitment and retention rates, ultimately benefiting the clinical trial imaging market. Remote imaging can capture real-world data in patients' natural environments, providing valuable insights into treatment outcomes and patient experiences. This real-world evidence complements traditional trial data and supports the market's growth by offering a more comprehensive understanding of therapies' effectiveness. Remote imaging and telemedicine can lead to cost savings by reducing the expenses associated with on-site visits, including travel, accommodations, and site-related costs. These cost efficiencies can encourage more organizations to conduct clinical trials, thereby contributing to market growth. Remote imaging technologies can efficiently collect data from various sources, reducing the time and effort required for data acquisition. This streamlining of data collection processes benefits both sponsors and research organizations, fostering growth in the market. Telemedicine and remote imaging facilitate global clinical trials by connecting researchers, patients, and healthcare providers from different regions. This globalization expands the market's reach and opportunities for collaboration. Advances in telemedicine technologies prioritize data security and compliance with privacy regulations. Ensuring the confidentiality and integrity of patient data contributes to trust and confidence in remote imaging solutions, driving their adoption and, consequently, market growth.

## Key Market Trends

### Artificial Intelligence (AI) Integration

AI algorithms can automate image analysis tasks, such as lesion detection, tumor measurement, and tissue segmentation. This automation reduces the reliance on manual assessments, accelerates data processing, and ensures consistency across multiple sites and time points, ultimately speeding up clinical trials. AI-powered image analysis is highly precise and consistent. It can detect subtle changes in images that may go unnoticed by human observers, leading to more accurate and reliable data. This accuracy is critical for assessing treatment responses and making informed decisions about drug development. AI can identify imaging biomarkers and patient characteristics that contribute to treatment responses. By analyzing large datasets, AI can help researchers stratify patients more effectively, enabling more targeted and personalized clinical trials. AI algorithms can predict treatment outcomes based on imaging data and patient profiles. This capability allows researchers to identify potential responders and

non-responders early in a trial, optimizing patient selection and reducing trial costs. AI-driven automation reduces the time and resources required for manual image analysis. This cost efficiency is attractive to pharmaceutical companies and research organizations, encouraging them to integrate AI into their clinical trials and imaging processes. AI can integrate imaging data with other types of data, such as genomics and clinical records. This holistic approach provides a comprehensive view of patients and their responses to treatment, fostering more in-depth research and insights.

### Advanced Imaging Modalities

Advanced imaging modalities, such as positron emission tomography (PET), magnetic resonance imaging (MRI), and diffusion-weighted imaging (DWI), provide detailed insights into disease characteristics, enabling more accurate diagnoses and treatment assessments. This expanded diagnostic capability is critical for trials focused on complex diseases. Advanced modalities are often more sensitive and specific, allowing for the early detection of diseases and abnormalities. This early detection is crucial in clinical trials, as it can lead to earlier intervention and more successful treatment outcomes. Advanced modalities often provide quantitative data, allowing for precise measurements of disease progression, treatment responses, and anatomical changes. This quantitative information enhances data accuracy and reproducibility in clinical trials. Techniques like functional MRI (fMRI) and PET enable researchers to study the functional and molecular aspects of diseases. This helps in understanding disease mechanisms, identifying therapeutic targets, and assessing treatment effects on a deeper level. Advanced imaging modalities support the development of personalized treatment strategies. By characterizing disease subtypes and patient responses, they enable researchers to tailor therapies to individual patients, a trend that aligns with precision medicine approaches. The combination of multiple advanced imaging modalities, such as PET-MRI or PET-CT, allows researchers to obtain complementary information from different aspects of a disease. This comprehensive data approach is advantageous for clinical trials. Advanced imaging modalities offer the ability to monitor treatment responses in real time. Researchers can observe how diseases and patients are responding to therapies, enabling prompt adjustments to treatment protocols.

### Segmental Insights

#### End-Use Insights

Based on the End-Use, the Pharmaceutical and biotechnology companies' segment is anticipated to witness substantial market growth throughout the forecast period.

Pharmaceutical and biotechnology companies are the primary sponsors of clinical trials. They drive the demand for imaging services by incorporating imaging endpoints into their trial protocols. As they conduct numerous trials across various therapeutic areas, their demand for imaging services and technologies is substantial, contributing to market growth. The pharmaceutical and biotechnology industries are constantly engaged in research and development activities. Their pursuit of innovative therapies and drug candidates leads to a growing number of clinical trials. Many of these trials involve imaging for safety assessments, efficacy evaluations, and patient stratification. These companies invest heavily in research and development, driving technological advancements in imaging modalities, analysis software, and data management systems. Their pursuit of more efficient and precise imaging methods benefits the entire clinical trial imaging market. Pharmaceutical and biotechnology companies are increasingly recognizing the value of imaging biomarkers in clinical trials. They incorporate imaging biomarkers into their research, driving the discovery and validation of new biomarker candidates. The trend toward precision medicine aligns with the objectives of many pharmaceutical and biotechnology companies. They use imaging data to stratify patients based on their responses to treatment, helping to identify target populations and personalize therapies. These companies conduct clinical trials on a global scale to access diverse patient populations and expedite drug development. Imaging technologies are crucial for standardizing data collection across different regions, making global trials feasible.

### Modality Insights

Based on the Modality segment, the computed tomography segment has been the dominant force in the market. CT scans are essential for assessing disease status and progression in clinical trials. They provide detailed 3D images of internal structures, allowing researchers to visualize tumors, lesions, and anatomical changes with high precision. CT imaging is crucial for evaluating the safety of investigational treatments. It helps identify potential adverse events, such as changes in organ function or the development of side effects, contributing to the comprehensive assessment of a therapy's safety profile. CT scans are used to assess treatment responses in clinical trials. By comparing baseline scans with follow-up images, researchers can determine how patients are responding to a therapy, whether tumors are shrinking or stabilizing, and if the treatment is achieving its intended goals. In many clinical trials, patient stratification based on disease stage and severity is critical. CT scans provide objective data for patient categorization, ensuring that participants are appropriately selected for specific trial arms or subgroups. CT imaging often serves as a primary or secondary endpoint in clinical trial protocols. It provides quantifiable and standardized data, making

it suitable for demonstrating treatment efficacy and obtaining regulatory approvals. CT scans are frequently integrated with other imaging modalities like PET and MRI to provide complementary information. This multimodal approach enhances the depth and accuracy of data collected in clinical trials. CT imaging is integral to precision medicine trials. It helps identify patient subpopulations that may benefit from targeted therapies, leading to more effective and personalized treatment strategies.

## Regional Insights

North America, specifically the Clinical Trial Imaging Market, dominated the market in 2023, primarily due to North America is home to a substantial number of pharmaceutical and biotechnology companies. These organizations are major consumers of clinical trial imaging services, driving demand for imaging technologies and expertise. The region conducts a high volume of clinical trials, covering a wide range of therapeutic areas. This extensive clinical trial activity generates significant demand for imaging services to assess safety, efficacy, and treatment responses. North America boasts world-renowned academic and research institutions. These organizations often collaborate with pharmaceutical companies to conduct clinical trials and research, with imaging playing a pivotal role. The region is a leader in the development and adoption of cutting-edge imaging technologies. It is a hub for research and development in medical imaging modalities, analysis software, and imaging biomarker discovery. Regulatory agencies such as the U.S. Food and Drug Administration (FDA) and Health Canada set standards and guidelines for clinical trials, including those involving imaging. Their influence extends beyond North America, as many international trials align with these regulatory standards. North America has a well-established infrastructure for conducting clinical trials. It has a network of specialized clinical trial centers, hospitals, and research facilities equipped with advanced imaging capabilities.

## Key Market Players

Clario Medical Imaging Inc

Icon PLC

Ixico PLC

Koninklijke Philips N.V

Medpace



Navitas Clinical Research, Inc

Parexel International Corporation

ProScan Imaging

Radiant Sage LLC

Resonance Health

Report Scope:

In this report, the Global Clinical Trial Imaging Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Clinical Trial Imaging Market,By Product and Service:

- oTrial Design Consulting Services

- oRead Analysis Services

- oOperational Imaging Services

- oImaging Software

Clinical Trial Imaging Market,By Modality:

- oMagnetic Resonance Imaging

- oComputed Tomography

- oUltrasound

- oPositron Emission Tomography

- oX-Ray

- oEchocardiography

- oOther Modalities

Clinical Trial Imaging Market,By End User:

- oPharmaceutical Biotechnology Companies

- oMedical Device Manufacturers

- oAcademic and Government Research Institute

Clinical Trial Imaging Market, By Region:

- oNorth America

  - United States

  - Canada

  - Mexico

- oEurope

  - France

  - United Kingdom

  - Italy

  - Germany

  - Spain

- oAsia-Pacific

  - China

India

Japan

Australia

South Korea

oSouth America

Brazil

Argentina

Colombia

oMiddle East Africa

South Africa

Saudi Arabia

UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Clinical Trial Imaging Market.

Available Customizations:

Global Clinical Trial Imaging market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

## Company Information

Detailed analysis and profiling of additional market players (up to five).

## Contents

### **1.PRODUCT OVERVIEW**

- 1.1.Market Definition
- 1.2.Scope of the Market
  - 1.2.1.Markets Covered
  - 1.2.2.Years Considered for Study
  - 1.2.3.Key Market Segmentations

### **2.RESEARCH METHODOLOGY**

- 2.1.Objective of the Study
- 2.2.Baseline Methodology
- 2.3.Key Industry Partners
- 2.4.Major Association and Secondary Sources
- 2.5.Forecasting Methodology
- 2.6.Data Triangulation Validation
- 2.7.Assumptions and Limitations

### **3.EXECUTIVE SUMMARY**

- 3.1.Overview of the Market
- 3.2.Overview of Key Market Segmentations
- 3.3.Overview of Key Market Players
- 3.4.Overview of Key Regions/Countries
- 3.5.Overview of Market Drivers, Challenges, Trends

### **4.VOICE OF CUSTOMER**

### **5.GLOBALCLINICAL TRIAL IMAGING MARKETOUTLOOK**

- 5.1.Market Size Forecast
  - 5.1.1.By Value
- 5.2.Market Share Forecast
  - 5.2.1.By Product Service (Trial Design Consulting Services, Read Analysis Services, Operational Imaging Services, Imaging Software)
  - 5.2.2.By Modality (Magnetic Resonance Imaging, Computed Tomography, Ultrasound, Positron Emission Tomography, X-Ray, Echocardiography, Other Modalities)

5.2.3.By End-User (Pharmaceutical Biotechnology Companies, Medical Device Manufacturers, Academic and Government Research Institute)

5.2.4.By Region (North America, Europe, Asia Pacific, South America, Middle East Africa)

5.2.5.By Company (2023)

5.3.Market Map

5.3.1 ByProduct Service

5.3.2 By Modality

5.3.3 By End-User

5.3.4 By Region

## **6.NORTH AMERICA CLINICAL TRIAL IMAGING MARKET OUTLOOK**

6.1.Market Size Forecast

6.1.1.By Value

6.2.Market Share Forecast

6.2.1.ByProduct Service

6.2.2.By Modality

6.2.3.By End-User

6.2.4.By Country

6.3.North America: Country Analysis

6.3.1.United States Clinical Trial Imaging Market Outlook

6.3.1.1.Market Size Forecast

6.3.1.1.1.By Value

6.3.1.2.Market Share Forecast

6.3.1.2.1.By Product Service

6.3.1.2.2.By Modality

6.3.1.2.3.By End-User

6.3.2.Canada Clinical Trial Imaging Market Outlook

6.3.2.1.Market Size Forecast

6.3.2.1.1.By Value

6.3.2.2.Market Share Forecast

6.3.2.2.1.By Product Service

6.3.2.2.2.By Modality

6.3.2.2.3.By End-User

6.3.3.Mexico Clinical Trial Imaging Market Outlook

6.3.3.1.Market Size Forecast

6.3.3.1.1.By Value

6.3.3.2.Market Share Forecast

- 6.3.3.2.1.By Product Service
- 6.3.3.2.2.By Modality
- 6.3.3.2.3.By End-User

## **7.EUROPE CLINICAL TRIAL IMAGING MARKET OUTLOOK**

### 7.1.Market Size Forecast

- 7.1.1.By Value

### 7.2.Market Share Forecast

- 7.2.1.By Product Service
- 7.2.2.By Modality
- 7.2.3.By End-User
- 7.2.4.By Country

### 7.3.Europe: Country Analysis

#### 7.3.1.France Clinical Trial Imaging Market Outlook

- 7.3.1.1.Market Size Forecast
  - 7.3.1.1.1.By Value
- 7.3.1.2.Market Share Forecast
  - 7.3.1.2.1.By Product Service
  - 7.3.1.2.2.By Modality
  - 7.3.1.2.3.By End-User

#### 7.3.2.Germany Clinical Trial Imaging Market Outlook

- 7.3.2.1.Market Size Forecast
  - 7.3.2.1.1.By Value
- 7.3.2.2.Market Share Forecast
  - 7.3.2.2.1.By Product Service
  - 7.3.2.2.2.By Modality
  - 7.3.2.2.3.By End-User

#### 7.3.3.United Kingdom Clinical Trial Imaging Market Outlook

- 7.3.3.1.Market Size Forecast
  - 7.3.3.1.1.By Value
- 7.3.3.2.Market Share Forecast
  - 7.3.3.2.1.By Product Service
  - 7.3.3.2.2.By Modality
  - 7.3.3.2.3.By End-User

#### 7.3.4.Italy Clinical Trial Imaging Market Outlook

- 7.3.4.1.Market Size Forecast
  - 7.3.4.1.1.By Value
- 7.3.4.2.Market Share Forecast

- 7.3.4.2.1.By Product Service
- 7.3.4.2.2.By Modality
- 7.3.4.2.3.By End-User
- 7.3.5.Spain Clinical Trial Imaging Market Outlook
  - 7.3.5.1.Market Size Forecast
    - 7.3.5.1.1.By Value
  - 7.3.5.2.Market Share Forecast
    - 7.3.5.2.1.By Product Service
    - 7.3.5.2.2.By Modality
    - 7.3.5.2.3.By End-User

## **8.ASIA-PACIFIC CLINICAL TRIAL IMAGING MARKET OUTLOOK**

- 8.1.Market Size Forecast
  - 8.1.1.By Value
- 8.2.Market Share Forecast
  - 8.2.1.By Product Service
  - 8.2.2.By Modality
  - 8.2.3.By End-User
  - 8.2.4.By Country
- 8.3.Asia-Pacific: Country Analysis
  - 8.3.1.China Clinical Trial Imaging Market Outlook
    - 8.3.1.1.Market Size Forecast
      - 8.3.1.1.1.By Value
    - 8.3.1.2.Market Share Forecast
      - 8.3.1.2.1.By Product Service
      - 8.3.1.2.2.By Modality
      - 8.3.1.2.3.By End-User
  - 8.3.2.India Clinical Trial Imaging Market Outlook
    - 8.3.2.1.Market Size Forecast
      - 8.3.2.1.1.By Value
    - 8.3.2.2.Market Share Forecast
      - 8.3.2.2.1.By Product Service
      - 8.3.2.2.2.By Modality
      - 8.3.2.2.3.By End-User
  - 8.3.3.Japan Clinical Trial Imaging Market Outlook
    - 8.3.3.1.Market Size Forecast
      - 8.3.3.1.1.By Value
    - 8.3.3.2.Market Share Forecast



- 8.3.3.2.1.By Product Service
- 8.3.3.2.2.By Modality
- 8.3.3.2.3.By End-User
- 8.3.4.South Korea Clinical Trial Imaging Market Outlook
  - 8.3.4.1.Market Size Forecast
    - 8.3.4.1.1.By Value
  - 8.3.4.2.Market Share Forecast
    - 8.3.4.2.1.By Product Service
    - 8.3.4.2.2.By Modality
    - 8.3.4.2.3.By End-User
- 8.3.5.Australia Clinical Trial Imaging Market Outlook
  - 8.3.5.1.Market Size Forecast
    - 8.3.5.1.1.By Value
  - 8.3.5.2.Market Share Forecast
    - 8.3.5.2.1.By Product Service
    - 8.3.5.2.2.By Modality
    - 8.3.5.2.3.By End-User

## **9.SOUTH AMERICA CLINICAL TRIAL IMAGING MARKET OUTLOOK**

- 9.1.Market Size Forecast
  - 9.1.1.By Value
- 9.2.Market Share Forecast
  - 9.2.1.By Product Service
  - 9.2.2.By Modality
  - 9.2.3.By End-User
  - 9.2.4.By Country
- 9.3.South America: Country Analysis
  - 9.3.1.Brazil Clinical Trial Imaging Market Outlook
    - 9.3.1.1.Market Size Forecast
      - 9.3.1.1.1.By Value
    - 9.3.1.2.Market Share Forecast
      - 9.3.1.2.1.By Product Service
      - 9.3.1.2.2.By Modality
      - 9.3.1.2.3.By End-User
  - 9.3.2.Argentina Clinical Trial Imaging Market Outlook
    - 9.3.2.1.Market Size Forecast
      - 9.3.2.1.1.By Value
    - 9.3.2.2.Market Share Forecast

- 9.3.2.2.1.By Product Service
- 9.3.2.2.2.By Modality
- 9.3.2.2.3.By End-User
- 9.3.3.Colombia Clinical Trial Imaging Market Outlook
  - 9.3.3.1.Market Size Forecast
    - 9.3.3.1.1.By Value
  - 9.3.3.2.Market Share Forecast
    - 9.3.3.2.1.By Product Service
    - 9.3.3.2.2.By Modality
    - 9.3.3.2.3.By End-User

## **10.MIDDLE EAST AND AFRICA CLINICAL TRIAL IMAGING MARKET OUTLOOK**

- 10.1.Market Size Forecast
  - 10.1.1.By Value
- 10.2.Market Share Forecast
  - 10.2.1.By Product Service
  - 10.2.2.By Modality
  - 10.2.3.By End-User
  - 10.2.4.By Country
- 10.3.MEA: Country Analysis
  - 10.3.1.South Africa Clinical Trial Imaging Market Outlook
    - 10.3.1.1.Market Size Forecast
      - 10.3.1.1.1.By Value
    - 10.3.1.2.Market Share Forecast
      - 10.3.1.2.1.By Product Service
      - 10.3.1.2.2.By Modality
      - 10.3.1.2.3.By End-User
  - 10.3.2.Saudi Arabia Clinical Trial Imaging Market Outlook
    - 10.3.2.1.Market Size Forecast
      - 10.3.2.1.1.By Value
    - 10.3.2.2.Market Share Forecast
      - 10.3.2.2.1.By Product Service
      - 10.3.2.2.2.By Modality
      - 10.3.2.2.3.By End-User
  - 10.3.3.UAE Clinical Trial Imaging Market Outlook
    - 10.3.3.1.Market Size Forecast
      - 10.3.3.1.1.By Value
    - 10.3.3.2.Market Share Forecast

- 10.3.3.2.1.By Product Service
- 10.3.3.2.2.By Modality
- 10.3.3.2.3.By End-User

## **11.MARKET DYNAMICS**

- 11.1.Drivers
- 11.2.Challenges

## **12.MARKET TRENDS DEVELOPMENTS**

- 12.1.Recent Development
- 12.2.Mergers Acquisitions
- 12.3.Product Launches

## **13.GLOBAL CLINICAL TRIAL IMAGING MARKET: SWOT ANALYSIS**

## **14.PORTER'S FIVE FORCES ANALYSIS**

- 14.1.Competition in the Industry
- 14.2.Potential of New Entrants
- 14.3.Power of Suppliers
- 14.4.Power of Customers
- 14.5.Threat of Substitute Products

## **15.COMPETITIVE LANDSCAPE**

- 15.1.Clario Medical Imaging Inc
  - 15.1.1.Business Overview
  - 15.1.2.Product Offerings
  - 15.1.3.Recent Developments
  - 15.1.4.Financials (As Reported)
  - 15.1.5.Key Personnel
  - 15.1.6.SWOT Analysis
- 15.2.Icon PLC
- 15.3.Ixico PLC
- 15.4.Koninklijke Philips N.V
- 15.5.Medpace
- 15.6.Navitas Clinical Research, Inc

15.7.Parexel International Corporation

15.8.ProScan Imaging

15.9.Radiant Sage LLC

15.10.Resonance Health

## **16.STRATEGIC RECOMMENDATIONS**

## **17.ABOUT US DISCLAIMER**

## I would like to order

Product name: Clinical Trial Imaging Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product and Service (Trial Design Consulting Services, Read Analysis Services, Operational Imaging Services, Imaging Software), By Modality (Magnetic Resonance Imaging, Computed Tomography, Ultrasound, Positron Emission Tomography, X-Ray, Echocardiography, Other Modalities), By End-User (Pharmaceutical & Biotechnology Companies, Medical Device Manufacturers, Academic and Government Research Institute), By Region, By Competition, 2019-2029F

Product link: <https://marketpublishers.com/r/C5B6A71CA7B3EN.html>

Price: US\$ 4,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C5B6A71CA7B3EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970